Enhancing Access with Direct to Inject Buprenorphine: Evidence and Implementation

Saturday, April 25, 2026

10:45 AM - 12:00 PM PT

Location: Harbor D-F, Level 2

Presenter(s)

JL

Josh Luftig, PA-C

Clinical Director & Co-Founder
The Bridge Center at The Public Health Institute
Point Reyes Station, California

Slides
Arianna D. Campbell, DMSc, MPH, PA-C, CAQ-EM, DFAAPA

Senior Director, M-PI
The Bridge Center at The Public Health Institute
Placerville, California

Handouts
AH

Andrew A. Herring, MD

Chief of Addiction Medicine
Alameda Health System
Oakland, California

Explore the latest evidence and practical implementation strategies for Direct-to-Inject extended-release buprenorphine, an innovative approach that eliminates traditional barriers to treatment initiation. This presentation synthesizes emerging research from emergency departments, inpatient settings, community clinics, and street medicine while providing actionable guidance for clinicians seeking to expand access to medications for opioid use disorder in their practice environments. Attendees will gain concrete knowledge to inform program development and clinical decision-making.

Learning Objectives:

Learners will be able to:

describe the current evidence supporting Direct-to-Inject extended-release buprenorphine including safety profile, patient outcomes, and treatment retention data.
compare implementation models for DTI buprenorphine across diverse healthcare settings including emergency departments, inpatient units, community clinics, and street medicine programs.
formulate an implementation approach for DTI buprenorphine appropriate to their specific practice setting and patient population.

Disclosure(s):

Josh Luftig, PA-C: No financial relationships to disclose

Arianna D. Campbell, DMSc, MPH, PA-C, CAQ-EM, DFAAPA: No financial relationships to disclose

Andrew A. Herring, MD: No financial relationships to disclose